A study to investigate the effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) compared with placebo MDI on heart and lung function in participants with chronic obstructive pulmonary disease (COPD)

Trial Identifier: D5980C00048
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: November 2025
Primary Completion Date: March 2027
Study Completion Date: March 2027
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.